Companies featured in this edition of the newsletter: ACTC, CHIP, CUR, CVM, ENZ, IMUC, IWEB, SRCO, SVUL, XSNX

Markets finally snapped their winning streak last week, as weakness in housing markets and durable goods orders led to broad-based declines in all of the major indices. All told, the Dow surrendered 155 points on the week to close at 9665, down 1.6% on the week but up 10.1% on the year. The Nasdaq lost 2.0% on the week to close at 2090, up 32.6% on the year, while the S&P 500 and Russell 2000 posted losses of 2.2% and 3.1% respectively, paring their yearly gains to 15.6% and 19.9%.

Unexpectedly poor data from the housing sector was the big economic story on the week as both new and existing August home sales failed to live up to expectations. New home sales increased modestly to 429,000, falling short of estimates calling

Companies featured in this edition of the newsletter: ACTC, CVM, CUR, DKAM, ENZ, IMUC, IWEB, PHC, SVUL, SRCO, SVUL, XSNX

Markets extended their winning streak yet again this week, as all ten sectors of the S&P 500 finished in positive territory and markets hit fresh highs for the year once again, despite the lack of any significant developments on either the corporate or economic fronts. All told, the Dow ended up 2.2% on the week, gaining 214 points to close at 9820 on the week, up 11.9% on the year. The Nasdaq performed slightly better, gaining 2.5% on the week, closing at 2132, up 35.2% on the year, while the S&P 500 and Russell 2000 gained 2.5% and 4.1% respectively, up 18.3% and 23.7% on the year.

While it was a relatively quiet week as far as headlines were concerned, there were some positive economic developments in the form

Companies featured in this edition of the newsletter: CUR, CVM, ENZ, IMUC, MBCI, ONEZ, PHC, SVUL

Markets finished in positive territory yet again during this holiday shortened week despite the lack of any significant developments on either the corporate or economic fronts. All told, the Dow gained 164 points to close at 9605, up 1.7% on the week and 9.4% on the year. The Nasdaq gained 3.1% on the week, closing at 2080, up 32% on the year, while the S&P 500 and Russell 2000 gained 2.6% and 4.0% respectively on the week, up 15.4% and 18.8% on the year.

It was a slow week on the corporate side, but there were some healthy signals from the technology sector, as Texas Instruments raised its Q3 outlook, guiding for EPS of between $0.37 and $0.41, up from previous forecasts of $0.29-$0.39. Fed Ex also guided higher, citing cost management and better

ImmunoCellular Therapeutics, Ltd., a Los Angeles-based clinical-stage company that is developing immune based therapies for the treatment of brain and other cancers, recently announced that the company has entered into a research and license option agreement regarding its ICT-69 antibody with Roche Group (SWX: ROG.VX; RO.S, OTCQX: RHHBY). As one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics, Roche Group will pay royalties to ImmunoCellular Therapeutics based on the company’s worldwide sales of ICT-69 products.

Under the terms of the agreement, ImmunoCellular Therapeutics will license to Roche the rights to investigate the potential of ICT-69 in the diagnosis and treatment of multiple myeloma and ovarian cancer. ICT-69 is one of several monoclonal antibodies currently being developed for multiple cancer indications by ImmunoCellular Therapeutics. Following the evaluation period, Roche has the right to acquire for an option exercise payment a commercial license for ICT-69 from

Companies featured in this edition of the newsletter: CVM, ICLK, IMUC, ITUI, IWEB, MBCI, NXOI, OMCM, ONEZ, PHC, SRCO, SVUL, XCR

Markets closed moderately higher yet again this week, as mostly better than expected economic data helped stave off profit taking to leave most indices in positive territory on the week. All told, the Dow ended the week up 0.4%, closing at 9544, up 38 points, bringing its YTD gains to 8.7%. The Nasdaq also gained 0.4% on the week to close at 2028, bringing its yearly gains to 28.6%, while the S&P 500 gained 0.3% and the Russell 2000 lost 0.3%, bringing their yearly gains to 13.9% and 16.1% respectively.

Economic news was in focus yet again this week in the absence of any market driving earnings data, as new home sales for July rose at 9.6%, posting its strongest gains since 2005. This positive development coupled with

Companies featured in this edition of the newsletter: CVM, ICLK, IMUC, ITUI, IWEB, MBCI, NXOI, OMCM, ONEZ, PHC, SRCO, SVUL, XCR

Markets closed moderately higher yet again this week, as mostly better than expected economic data helped stave off profit taking to leave most indices in positive territory on the week. All told, the Dow ended the week up 0.4%, closing at 9544, up 38 points, bringing its YTD gains to 8.7%. The Nasdaq also gained 0.4% on the week to close at 2028, bringing its yearly gains to 28.6%, while the S&P 500 gained 0.3% and the Russell 2000 lost 0.3%, bringing their yearly gains to 13.9% and 16.1% respectively.

Economic news was in focus yet again this week in the absence of any market driving earnings data, as new home sales for July rose at 9.6%, posting its strongest gains since 2005. This positive development coupled with

ImmunoCellular Therapeutics, Ltd. announced this morning that it has been granted a U.S. patent relating to its monoclonal antibody therapeutics. Patent No. 7,498,129 entitled “Myeloma Cell and Ovarian Cancer Cell Surface Glycoproteins, Antibodies Thereto, and Uses Thereof,” covers the use of IMUC’s antibodies to measure the effectiveness of the company’s proposed treatment of multiple myeloma and ovarian cancer using the company’s proprietary molecular antibodies.

“This patent provides additional strength to the growing intellectual property position that we are building around our antibody technologies for the detection and the treatment of cancer,” stated Manish Singh, Ph.D., president and chief executive officer of IMUC. “We are actively exploring potential partnering opportunities to enable us to bring these promising technologies through clinical testing and commercialization.”

“I am very encouraged by the preclinical data that we’re observing with these antibodies, most notably their high specificity for binding to multiple myeloma and ovarian cancer, and